Business and Finance

There are currently 100,000 doses standing by

$180M collaboration aims to introduce multiple vaccine candidates in 2022

Two-dose COVAXIN currently under EUA in India

CDMO to take over operations, including equipment and workforce, at site in Couvet, Switzerland

Deal completes Verista's lifecycle support for pharma, which now includes consulting, technology and manufacturing

Agreement provides Acentrus with specialty pharmacy accreditation

In Phase III at the moment, mRNA dose will be produced at Bayer's Wuppertal, Germany facility

Production expected to begin in the second quarter

Forms three new business units to integrate healthcare services

Komodo-BHI agreement grows patient database to 325M

Technology partnership focused on improving patient-level data integration

Terms provide equitable access to Covid-19 vaccine

Cold-chain deal strives to contribute to vaccine distribution efforts

Powered by AI analytics, healthcare partnership aims to increase member engagement

Latest air cargo collaboration provides pandemic response support

Acquisition of point-of-care diagnostics provider could reach upwards of $550M

Alliance strives to develop novel AAV vectors

Secures $76M in funding for Boston-area manufacturing and innovation center

Goal is to merge companies’ digital therapeutics and technology expertise

Adding Henogen S.A. furthers its efforts in cell and gene-based therapy development

Deal is expected to increase simplicity of EHR communication

Strategic growth partnership will help company's 'digital hub' transformation

Agreement with Amgen includes payments possibly totaling over $240M

Acquires Kymab in deal worth up to $1.45B

Partnership with Latin American packager aims to strengthen local reach

SK Capital expected to take ownership of CDMO business in April

If approved, partnership could supply hundreds of millions of doses

Will establish a new large-scale cell culture manufacturing facility

Deal boosts ABC's global reach, allows Walgreens to focus on further retail growth

Deal gives Angelini epilepsy asset, which could gain European approval this year